GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

researchers examined nutrient intake when using a glucagon-like peptide 1 receptor agonist (GLP-1RA). Obesity prevalence has doubled since 1990, with one in eight individuals being obese worldwide.

Novo Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new entrants. 7.4 Where Are GLP-1RAs Expected to Position in the Future Chronic Kidney ...

Adjusted hazards ratios calculated using Cox regression represent ratios of the incidence of composite obesity-related cancer and all-cause death in matched pairs of patients prescribed GLP-1RA versus ...

However, the benefit of GLP-1RA treatment after bariatric surgery for the primary prevention of MACE is unclear. To address this gap, researchers analyzed electronic health record data for ...

GLP-1RA medications are best known for helping control type 2 diabetes and treat obesity. They mimic a hormone in the body, GLP-1, that lowers blood sugar levels and makes people feel fuller for ...

Embla is now making its approach available to U.S. employers as an alternative to high-dose GLP-1 programs. "GLP-1s are powerful tools, but the tools too often become the treatment. When care is ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA asset tirzepatide, respectively sold under the brand names Zepbound and ...

They had no prior history of cancer and either underwent bariatric surgery or took GLP-1RA medications. These medications mimic the GLP-1 hormone. This can help make people feel fuller for longer ...

Published across four peer-reviewed journals, this consensus-based guidance reflects an interdisciplinary collaboration to help clinicians support patients receiving GLP-1 receptor agonists for ...